Global Talent Acquisition at George Clinical | Life Sciences Recruitment Expert | CRO Talent Strategy
"99% of clinical-stage biotechs with investments in 2024 are moving away from CROs to run their trials." OK, that was bait! Let's be honest: These sensational percentages are designed to catch your attention but lack real backing. No comprehensive studies support such bold assertions. What’s actually happening? Companies are becoming more strategic with their spending. The clinical research landscape is returning to pre-COVID norms, allowing companies to be more selective in their vendor choices. CROs are adapting too, becoming more flexible and responsive to their clients' needs. This means Biotechs and Pharma companies are now more involved in their trials, sites, and overall quality management. We’re witnessing a shift from quantity to quality, which is fantastic. As a recruiter, this is where I excel: delivering QUALITY swiftly. How do I achieve this? My sole focus is networking with clinical professionals. I'm not executing trials, setting up SOPs, or selecting vendors. My job is to connect with exceptional CRAs, CTMs, PMs, and VPs of Clinical Operations, aligning my efforts with my clients' needs. In today's uncertain climate, with investments being scrutinized and upcoming elections causing uncertainty, everyone is aiming for the best quality. The market is still active, and there's demand for CROs, consultants, recruiters, and agencies. The common goal? High quality. Do you agree? What are your thoughts? #ClinicalOperationsRecruitment #Quality #CRO #Biotech
Selina B.
7 个月
From a freelancer perspective I have seen here in the UK a significant shift away from using freelancers in Study management by Pharma to using CROs utilising the FSP model essentially cutting out the middleman … me the contractor…….whenever a rare freelance 6 month or 1 year contract comes available with big Pharma there is deluge of contractors now applying for the scraps of work that over the past 20 years of my time contracting that I once took for granted of repeat business. There is and will always be winners and losers.
Leo Brommet
7 个月
In clinical research quality should always prevail quantity!
Life Sciences Executive, Real-World Evidence Nerd, Passionate about Clinical Research
7 个月The CRO industry is in the midst of a painful but necessary evolution brought about by the widespread adoption of RWD and data-driven solutions to common clinical research challenges. Gone are the days when you could go head-to-head with competitors without setting yourself apart in the data realm. Proprietary data, the ability to incorporate agnostic data, and a team that knows how to use the tools at their disposal will set the next generation of service providers apart. It'll be interesting to see how things play out in the next 3-5 years since the downward financial pressure exerted on trial service providers already means they're challenged with lower margins, which could hamstring their ability to acquire the proprietary data they need to rise above the competition.